Medicinal chemistry perspective of pyrido[2,3-d]pyrimidines as anticancer agents

Adarsh Kumar; Kuber Kumar Bhagat; Ankit Kumar Singh; Harshwardhan Singh; Tanuja Angre; Amita Verma; Habibullah Khalilullah; Mariusz Jaremko; Abdul-Hamid Emwas; Pradeep Kumar

doi:10.1039/D3RA00056G

Medicinal chemistry perspective of pyrido[2,3-d]pyrimidines as anticancer agents

Adarsh Kumar,†^a Kuber Kumar Bhagat,†^a Ankit Kumar Singh,

^a Harshwardhan Singh,^a Tanuja Angre,^a Amita Verma,

^b Habibullah Khalilullah,^c Mariusz Jaremko,

^d Abdul-Hamid Emwas^e and Pradeep Kumar

*^a

Author affiliations

* Corresponding authors

^a Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Ghudda, Bathinda 151401, India
E-mail: pradeepyadav27@gmail.com

^b Bioorganic and Medicinal Chemistry Research Laboratory, Department of Pharmaceutical Sciences, Sam Higginbottom University of Agriculture Technology and Sciences, Prayagraj, India

^c Department of Pharmaceutical Chemistry and Pharmacognosy, Unaizah College of Pharmacy, Qassim University, Unayzah, Saudi Arabia
E-mail: h.abdulaziz@qu.edu.sa

^d Smart-Health Initiative and Red Sea Research Center, Division of Biological and Environmental Sciences and Engineering, King Abdullah University of Science and Technology, P.O. Box 4700, Thuwal 23955-6900, Saudi Arabia
E-mail: Mariusz.jaremko@kaust.edu.sa

^e King Abdullah University of Science and Technology, Core Labs, Thuwal 23955-6900, Saudi Arabia
E-mail: abdelhamid.emwas@kaust.edu.sa

Abstract

Cancer is a major cause of deaths across the globe due to chemoresistance and lack of selective chemotherapy. Pyrido[2,3-d]pyrimidine is an emerging scaffold in medicinal chemistry having a broad spectrum of activities, including antitumor, antibacterial, CNS depressive, anticonvulsant, and antipyretic activities. In this study, we have covered different cancer targets, including tyrosine kinase, extracellular regulated protein kinases – ABL kinase, phosphatidylinositol-3 kinase, mammalian target of rapamycin, p38 mitogen-activated protein kinases, BCR-ABL, dihydrofolate reductase, cyclin-dependent kinase, phosphodiesterase, KRAS and fibroblast growth factor receptors, their signaling pathways, mechanism of action and structure–activity relationship of pyrido[2,3-d]pyrimidine derivatives as inhibitors of the above-mentioned targets. This review will represent the complete medicinal and pharmacological profile of pyrido[2,3-d]pyrimidines as anticancer agents, and will help scientists to design new selective, effective and safe anticancer agents.

This article is part of the themed collection: 2023 Reviews in RSC Advances

RSC Advances

Medicinal chemistry perspective of pyrido[2,3-d]pyrimidines as anticancer agents

Abstract

Article information

Download Citation

Permissions

Medicinal chemistry perspective of pyrido[2,3-d]pyrimidines as anticancer agents

Social activity

Search articles by author

Spotlight

Advertisements